What Eden Biologics does

Eden Biologics is a clinical-stage biopharmaceutical company headquartered in Hsinchu, Taiwan, developing a portfolio of biosimilars targeting high-value originator biologics. Originally founded in 2012 as JHL Biotech, the company rebranded to Eden Biologics in February 2021 to refocus on proprietary biosimilar development after separating from its former contract development and manufacturing (CDMO) operations. The company's pipeline includes 13+ biosimilar candidates, with lead asset EB1001 (a Denosumab biosimilar) in Phase 3 clinical trials in Europe following regulatory approvals in Hungary and Poland in 2021. Other disclosed programs include EB05 (Rituximab) and EB06 (Trastuzumab), spanning oncology, bone disease, and immunology indications.

The company's technology is built around proprietary cell line development, analytical characterization, and cGMP-compliant biomanufacturing capabilities that historically underpinned both its internal biosimilar programs and external CDMO services. The CDMO business was divested to Bora Pharmaceuticals in July 2022 for approximately $50–65M, leaving Eden focused on advancing its pipeline toward regulatory approval and commercialization. The company has secured regulatory authorizations across 20+ jurisdictions and pursues biosimilar pathways under FDA, EMA, and TFDA frameworks.

Eden's business model is pre-revenue at the commercial level, with future revenue expected from biosimilar product sales, licensing, and partnership economics following regulatory approvals. The company has historically been funded through institutional equity rounds (cumulative approximately $266.6M from 2012–2018) from investors including KPCB, Sequoia Capital, Biomark Capital, Milestone Capital, Cathay Life Insurance, CDIB, and Sanofi (strategic investor, 2018), and has stated headcount of approximately 51–100 employees. The company is no longer publicly listed following delisting.

Name

Eden Biologics

Legal name

Eden Biologics, Inc.

Website

https://edenbiologics.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Eden Biologics is a Hsinchu, Taiwan-based clinical-stage biopharmaceutical company developing a pipeline of 13+ biosimilars, with lead asset EB1001 (Denosumab) in European Phase 3 trials following its 2022 CDMO divestiture to Bora Pharmaceuticals.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals / Biosimilars

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody (mAb) Biosimilars (HLAAAHAA)

akta.pro secondary industries

Monoclonal Antibody (mAb) Biosimilars (HLAIAFAA), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Biosimilar development
• Biologics manufacturing
• Monoclonal antibody therapeutics
• Contract development services
• Recombinant protein production

Headquarters

HQ city

Hsinchu

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Services: Contract Development and Manufacturing Organization services providing end-to-end biologics development from cell line development to commercial manufacturing with regulatory filing support. As of July 2022, the CDMO business unit was sold to Bora Pharmaceuticals, though Eden continues partnerships with CDMO providers Chime and Bora.
2. Proprietary Biosimilar Pipeline: Development and commercialization of proprietary biosimilar medicines. The company has more than 13 biosimilars in its pipeline portfolio including lead product EB1001 (Denosumab biosimilar) which has entered Phase 3 clinical trials. Revenue would come from product sales upon regulatory approvals.
3. Collaboration & Licensing: Licensing-in of innovative new molecules for co-development and licensing-out of proprietary technology platforms to partners for new and innovative biologics development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Eden Biologics develops and manufactures biosimilar medicines, with a pipeline of 13+ biosimilar candidates targeting multiple therapeutic areas. Its lead product, EB1001 (a proposed Denosumab biosimilar referencing Prolia/Xgeva), has entered Phase 3 clinical trials in Europe. Following the July 2022 sale of its CDMO business unit to Bora Pharmaceuticals, the company focuses on proprietary biosimilar development, collaboration, and licensing of its biologics technology platforms.

Product overview

Eden Biologics is a biopharmaceutical company that develops biosimilars and provides contract development and manufacturing services. The company's core offerings include EB1001, its lead Denosumab biosimilar currently in Phase 3 clinical trials, and a broader portfolio of 13+ biosimilar candidates. Prior to July 2022, Eden also operated a CDMO (Contract Development and Manufacturing Organization) business providing end-to-end biologics development services from cell line development to commercial manufacturing, which was sold to Bora Pharmaceuticals. The company also has a strategic collaboration with Q-Sera for RAPClot™ Rapid Serum tubes.

Differentiator

Problem solved

Functional benefit

Products and services

• EB1001 (Denosumab Biosimilar) Lead biosimilar product candidate targeting RANKL, designed as a proposed biosimilar to Prolia/Xgeva (Denosumab) for treatment of osteoporosis, giant cell tumors of bone, and skeletal-related events from metastatic solid tumors. Currently in Phase 3 clinical trials.
• Biosimilar Pipeline Portfolio Portfolio of 13+ biosimilars in development targeting various therapeutic areas, developed using experienced process optimization and innovative, cost-effective manufacturing infrastructure.
• RAPClot™ Rapid Serum Tubes Blood collection tubes coated with recombinant ecarin for rapid serum production, developed in collaboration with Q-Sera Pty Ltd using proprietary cell lines and protein expression technologies. The tubes use novel coagulation agents found in snake venom to rapidly clot blood samples.

Quantifiable outcome

• Phase 3 clinical trial approved in Europe for lead biosimilar EB1001 (Denosumab)
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• Bora Pharmaceuticals Co., Ltd.coreStrategic or Co-development Partner · 1 July 2022Acquisition of Eden's CDMO business unit by Bora Pharmaceuticals for US$50-65 million. The transaction combines Eden's biologics CDMO services with Bora's expanded pharmaceutical CDMO capabilities. Eden will now have two CDMO partners (Chime and Bora) while focusing on biosimilar development.
• Q-Sera Pty LtdcoreTechnology or Integration · 22 May 2020Strategic collaboration to produce high yielding recombinant ecarin for commercial scale production of RAPClot™ Rapid Serum tubes. JHL Biotech (now Eden Biologics) developed proprietary cell lines and protein expression technologies enabling Q-Sera to produce recombinant ecarin in higher yields at commercial scale. The tubes use novel coagulation agents found in snake venom to rapidly clot blood samples.
• Chime BiologicscoreStrategic or Co-development PartnerCDMO partner enabling Eden to deliver affordable and accessible medicines as part of their strategic partnership network.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Shanghai Henlius Biotech: China-based biosimilar developer with commercialized products (HLX01, HLX02, etc.) and strong oncology biosimilar pipeline. Comparable as an Asia-headquartered biosimilar pure-play; Eden Board member Dr. Scott Liu co-founded Henlius.
• Samsung Bioepis: Biosimilar-focused joint venture backed by Samsung and Biogen with multiple approved mAb biosimilars (Renflexis, Imraldi, Ontruzant). Comparable in target products, biosimilar pipeline strategy, and global commercialization approach.
• Biocon Biologics: India-based biosimilar business within Biocon with multiple approved biosimilars (Ogivri, Fulphila, Semglee) targeting oncology and autoimmune indications. Comparable mAb biosimilar pipeline and emerging-market commercialization focus.
• Celltrion: South Korean biosimilar developer with commercialized mAb biosimilars (Remsima/Inflectra, Truxima, Herzuma). Directly comparable to Eden as a pure-play biosimilar company developing and commercializing monoclonal antibody biosimilars globally.
• Alvotech: Iceland-based biosimilar company with multiple late-stage mAb biosimilars and integrated manufacturing. Highly comparable as a focused biosimilar developer targeting the same reference molecules and markets as Eden.
• Coherus Biosciences: US biosimilar-focused company with approved products (Udenyca, Yusimry, Cimerli). Comparable as a focused biosimilar developer and competitor in similar therapeutic areas including oncology supportive care.

Broad incumbents

• Amgen: Global biopharmaceutical incumbent that both develops originator biologics and markets multiple biosimilars (Amjevita, Kanjinti, Mvasi). Comparable as a competitor in the same biosimilar therapeutic categories, but operates across a vastly broader portfolio.
• Dr. Reddy's Laboratories: India-headquartered global pharmaceutical company with a biosimilars business; Eden CEO Dr. Steve Lee previously led Dr. Reddy's Biologics business. Comparable as a competitor with biologics manufacturing capability and global commercial reach.

Others

• Bora Pharmaceuticals: Taiwan-based CDMO that acquired Eden's CDMO business unit for US$50-65M in July 2022. Now serves as a manufacturing partner and is directly comparable on biologics CDMO capabilities previously housed within Eden.

Emerging players

• Fujifilm Kyowa Kirin Biologics: Biosimilar joint venture developing mAb biosimilars leveraging Fujifilm's manufacturing capabilities. Comparable as an emerging biosimilar developer with pipeline products targeting similar reference molecules.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eden Biologics